Trevi Therapeutics' Phase 2a CANAL Trial Data Presentation Details
![Trevi Therapeutics' Phase 2a CANAL Trial Data Presentation Details](https://investorshangout.com/images/blog/ihnews-Trevi%20Therapeutics%27%20Phase%202a%20CANAL%20Trial%20Data%20Presentation%20Details.jpg)
Trevi Therapeutics' Upcoming Oral Presentation at ERS Congress
Professor Jacky Smith will present research on the link between objective cough counts and improvements in patient-reported outcomes, focusing on the use of nalbuphine ER in patients with idiopathic pulmonary fibrosis (IPF).
Overview of the CANAL Trial Presentation
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a biopharmaceutical company in the clinical-stage, is set to present essential findings from the Phase 2a CANAL trial at the European Respiratory Society (ERS) Congress. The event will run from September 7-11 in Vienna, Austria, where the presentation is scheduled for September 8.
Details About the Congress
This year's ERS Congress aims to gather experts in respiratory medicine to share knowledge and advancements. The poster session will include research studies specifically dedicated to chronic cough.
Significance of the Data Presented
In his presentation, Prof. Smith will discuss how changes in cough frequency relate to improvements in the quality of life for patients using nalbuphine ER. Patient-reported outcomes are critical in clinical trials, addressing patients' experiences beyond clinical measurements. The demand for effective treatments for chronic cough in IPF is significant, and insights from this trial seek to address that gap.
Background on Trevi Therapeutics, Inc.
Trevi Therapeutics is at the forefront of developing the investigational therapy Haduvio™ (oral nalbuphine ER) aimed at treating chronic cough associated with IPF and refractory chronic cough (RCC). Haduvio operates as an extended-release medication that functions both centrally in the brain and peripherally in the lungs, showing promise in providing a dual approach to alleviating chronic cough symptoms.
Impact of Chronic Cough
The ramifications of chronic cough on patients are vast, often leading to a decline in quality of life across social, physical, and psychological domains. Particularly in IPF, chronic cough may exacerbate the disease, increasing the risk of progression and poor outcomes. Despite the high incidence of chronic cough among adults and its profound impact, there are currently no approved therapies available specifically targeting this condition.
Future Prospects for Haduvio
As Trevi hopes to finalize Haduvio as the official trade name for oral nalbuphine ER, it’s important to note that the drug's safety and efficacy remain pending evaluation by regulatory bodies. The company's efforts highlight the urgency of developing treatments for areas with considerable unmet needs.
Frequently Asked Questions
What is the focus of Trevi Therapeutics' research?
Trevi Therapeutics focuses on developing therapies, particularly Haduvio™, for chronic cough related to idiopathic pulmonary fibrosis and refractory chronic cough.
When will the data from the CANAL trial be presented?
The data will be presented on September 8 during the European Respiratory Society Congress.
Who is presenting the CANAL trial data?
Professor Jacky Smith, a renowned expert in the field, will present the findings.
Why are patient-reported outcomes significant?
Patient-reported outcomes provide deeper insights into how treatments affect patients' lives, serving as a vital feedback mechanism during clinical trials.
How does Haduvio work in treating chronic cough?
Haduvio, as an extended-release formulation, acts as a dual?-opioid receptor agonist and µ-opioid receptor antagonist, targeting cough mechanisms both in the central nervous system and the lungs.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Asian Markets Anticipate Major Economic Data Amid Uncertainty
- Kroger CEO Defends Price Hikes Amid Merger Trial Challenges
- Ensurge Micropower ASA Updates Employee Share Purchase Plan Details
- Ryman Hospitality Properties Announces Q3 Dividend Details
- Shuttle Pharma Shares Exciting Progress in Clinical Trials
- CSW Industrials Launches Public Offering of Common Stock
- SS&C Technologies Announces Details for 2024 Analyst Day
- URW SE Updates on Voting Rights and Share Capital Details
- Third Annual Chicago Drives Electric Event Details Revealed
- Federal Data Shows Progress on Bridge Repairs Nationwide
- Ipsen Reports Voting Rights and Share Capital Details
- Auction Details for RIKB 35 0917 Treasury Bonds
- Kipi.ai's Rebranding Journey: Embracing AI and Data Solutions
- Federal Reserve Data Insights: Rate Cuts Ahead?
- Data Annotation Market to Hit USD 29.6 Billion by 2033
- Industrial Cooling Systems Market Set for Remarkable Growth
- Automated Data Processing Market Growth and Trends Ahead
- Cineverse Expands Data Security with LiveRamp Integration
- Data Center Networking Sector Set for USD 76.87 Billion Growth
- Industrial Lubricants Market Growth to USD 68.42 Billion Soon
- Alpaca Real Estate Chooses Intapp DealCloud for Data Management
- GridGain to Showcase Real-Time Data Innovations at Conferences
- Fortress Biotech's Upcoming Presentation at Global Conference
- Outlook Therapeutics Completes Enrollment in NORSE EIGHT Trial
- Mobile Dealer Data Introduces ServiceVision™ for Efficiency
Recent Articles
- Investigation Launched into Definitive Healthcare Corp. (DH)
- Zscaler Reports Record Growth and Promising Future Revenues
- Consequences of the Chase Bank ATM Glitch Explained
- Strategic Joint Venture for Private Credit by Thornburg, Bow River
- Streamline Health Set to Release Q2 2024 Financial Results
- C3.ai Stock Response to Earnings: Cautious Outlook Dims Success
- Johnson & Johnson Boosts Talc Settlement to Resolve Legal Issues
- Shengfeng Development Announces Strong Growth for First Half 2024
- Aspen Pharmacare: Strong Revenue Growth Amid Challenges
- Market Trends Today: Nvidia's Fall and Labor Market Updates
- Are 401(k) Matching Contributions Beneficial for Everyone?
- Why September is Key for Verizon Stock Investors
- Discover Daily Wisdom with Immergo's Innovative OTT Platform
- US Shapewear Market Growth Driven by Sustainability Needs
- Rescue Village's Woofstock Raises Over $100,000 for Animals
- Google's Compliance Proposals Under EU Scrutiny for Fairness
- Asendia USA Celebrates Gold Sponsorship at eBay Open 2024
- Curran Group Enhances Community Engagement for Suicide Prevention
- Surging Odds for 50bps Fed Rate Cut This September
- Next Generation Sequencing Market to Reach USD 92.2 Billion
- Clouds of Care Secures 5 Million Euros for CNS Innovations
- SAS Recognized as Leader in AI and Machine Learning Platforms
- Endeavour Mining Updates on Major Shareholder Notification
- BIDFTA.COM Expands Auction Services with Bargain Hunt Deal
- Understanding Capital Gains Tax Exclusions on Home Sales